Seamus Fernandez
Stock Analyst at Guggenheim
(4.74)
# 71
Out of 5,182 analysts
131
Total ratings
64.29%
Success rate
26.36%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Reiterates: Buy | $1,183 | $948.45 | +24.73% | 26 | May 5, 2026 | |
| ACRS Aclaris Therapeutics | Initiates: Buy | $12 | $4.93 | +143.41% | 2 | May 5, 2026 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $27 → $25 | $7.71 | +224.25% | 2 | Apr 29, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $72 | $56.16 | +28.21% | 15 | Apr 8, 2026 | |
| GENB Generate Biomedicines | Initiates: Buy | $30 | $13.66 | +119.62% | 1 | Mar 24, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $130 → $160 | $83.03 | +92.70% | 9 | Mar 24, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $25 → $30 | $14.73 | +103.67% | 3 | Mar 19, 2026 | |
| TENX Tenax Therapeutics | Maintains: Buy | $25 → $34 | $11.66 | +191.60% | 4 | Mar 16, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $34 → $35 | $21.17 | +65.33% | 4 | Feb 27, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $140 → $143 | $94.17 | +51.85% | 4 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $116 | $53.01 | +118.83% | 5 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $140 | $39.10 | +258.06% | 3 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $77 → $88 | $40.97 | +114.82% | 5 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $43.31 | - | 1 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $5.37 | +104.84% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.22 | - | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $29.54 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $111.38 | +9.53% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $50.41 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.09 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $46.07 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $146.03 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.07 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $33.97 | +32.47% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $182.85 | -79.22% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $25.68 | +47.98% | 3 | Jan 31, 2018 |
Eli Lilly and Company
May 5, 2026
Reiterates: Buy
Price Target: $1,183
Current: $948.45
Upside: +24.73%
Aclaris Therapeutics
May 5, 2026
Initiates: Buy
Price Target: $12
Current: $4.93
Upside: +143.41%
Sagimet Biosciences
Apr 29, 2026
Maintains: Buy
Price Target: $27 → $25
Current: $7.71
Upside: +224.25%
Bristol-Myers Squibb Company
Apr 8, 2026
Reiterates: Buy
Price Target: $72
Current: $56.16
Upside: +28.21%
Generate Biomedicines
Mar 24, 2026
Initiates: Buy
Price Target: $30
Current: $13.66
Upside: +119.62%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $130 → $160
Current: $83.03
Upside: +92.70%
Amylyx Pharmaceuticals
Mar 19, 2026
Maintains: Buy
Price Target: $25 → $30
Current: $14.73
Upside: +103.67%
Tenax Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $25 → $34
Current: $11.66
Upside: +191.60%
Arcutis Biotherapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $21.17
Upside: +65.33%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Buy
Price Target: $140 → $143
Current: $94.17
Upside: +51.85%
Feb 2, 2026
Reiterates: Buy
Price Target: $116
Current: $53.01
Upside: +118.83%
Jan 20, 2026
Maintains: Buy
Price Target: $90 → $140
Current: $39.10
Upside: +258.06%
Jan 16, 2026
Maintains: Buy
Price Target: $77 → $88
Current: $40.97
Upside: +114.82%
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $43.31
Upside: -
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $5.37
Upside: +104.84%
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $9.22
Upside: -
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $29.54
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $111.38
Upside: +9.53%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $50.41
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.09
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $46.07
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $146.03
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $5.07
Upside: -
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $33.97
Upside: +32.47%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $182.85
Upside: -79.22%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $25.68
Upside: +47.98%